Crescent Biopharma, Inc. (CBIO) vs Phathom Pharmaceuticals, Inc. (PHAT)
A side-by-side comparison of Crescent Biopharma, Inc. and Phathom Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBIO
Crescent Biopharma, Inc.
$13.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PHAT
Phathom Pharmaceuticals, Inc.
$6.78HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CBIO vs PHAT
growth of $100 · dividends reinvested · last 7yCBIO -90.2% (-28.2%/yr)PHAT -72.8% (-17.0%/yr)PHAT compounded faster over this window
CBIO PHAT
CBIO vs PHAT: by the numbers
- •PHAT is the larger company ($549M vs $504M market cap).
- •Both run net losses; PHAT's is the smaller (-41.34% vs -1371.51% net margin).
Metrics side by side
Valuation
| Metric | CBIO | PHAT |
|---|---|---|
| P/S ratio | 42.42 | 2.29 |
| P/B ratio | 3.17 | N/A |
Profitability
| Metric | CBIO | PHAT |
|---|---|---|
| Gross margin | 100.00% | 82.92% |
| Operating margin | -1407.52% | -91.36% |
| Net margin | -1371.51% | -41.34% |
| ROE | -99.83% | N/A |
| ROIC | -102.59% | -23.45% |
Growth (annualized)
| Metric | CBIO | PHAT |
|---|---|---|
| Revenue CAGR (5Y) | 39.89% | N/A |
| Total return CAGR (5Y) | -24.40% | -26.93% |
Frequently asked
- How have CBIO and PHAT total returns compared?
- Over the past 5 years, CBIO delivered -24.40% and PHAT delivered -26.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Crescent Biopharma ROEPhathom Pharmaceuticals ROECrescent Biopharma operating marginPhathom Pharmaceuticals operating marginCrescent Biopharma revenue growthPhathom Pharmaceuticals revenue growthCrescent Biopharma free cash flowPhathom Pharmaceuticals free cash flow
Crescent Biopharma & Phathom Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.